Introduction
============

As Type 2 diabetes advances, progressive islet B-cell dysfunction leads to a deterioration in glycaemic control and most people eventually require insulin treatment, often at high doses because of insulin insensitivity \[[@b1]\]. One approach to optimizing the effectiveness of insulin is to continue oral glucose-lowering drugs (OGLDs) when starting insulin, rather than changing to insulin alone. Studies suggest that this reduces the insulin dose requirement by approximately 20% in combination with one oral agent, and approximately 40% with both a sulphonylurea and metformin, while achieving similar glycaemic control \[[@b2],[@b3]\].

In a 1-year study of previously insulin-naive people, combination metformin and bedtime insulin gave greater improvement in glycaemic control with less hypoglycaemia than bedtime insulin with sulphonylurea, sulphonylurea plus metformin, or morning insulin \[[@b4]\]. Body weight was unchanged with insulin and metformin, but increased in the other groups. People on maximum-tolerated doses of OGLDs who continued metformin with insulin used less insulin, had less weight gain, and achieved better glycaemic control compared with insulin plus placebo \[[@b5],[@b6]\]. Hence, guidelines recommend continuing metformin (and other OGLDs) when starting insulin \[[@b7],[@b8]\].

People with poor glucose control on metformin alone can benefit from addition of a thiazolidinedione \[[@b9],[@b10]\] and, in studies with rosiglitazone added to metformin, homeostasis model assessment (HOMA) estimates of insulin sensitivity and islet B-cell dysfunction also improved \[[@b11],[@b12]\]. This suggests the actions of the two drugs are complementary \[[@b13]--[@b16]\]. In addition, because gastrointestinal side-effects with metformin are dose related \[[@b17]\], a lower incidence can be achieved by combination with rosiglitazone through reduction of metformin dose \[[@b12]\]. There is also reduced weight gain compared with thiazolidinedione monotherapy \[[@b10],[@b18]\].

Adding rosiglitazone to insulin therapy was found to reduce glycated haemoglobin (HbA~1c~) by 1.2% (*P* \< 0.001), along with a 12% reduction of insulin dosage, but with increased oedema and weight gain \[[@b19],[@b20]\]. As the use of exogenous insulin is also associated with fluid retention, the tolerability of rosiglitazone and insulin in combination warrants further investigation.

While that study evaluated the addition of rosiglitazone to insulin \[[@b19]\], the effect of adding insulin to rosiglitazone, which would be the commoner clinical scenario, has not been studied. Many individuals are treated with a combination of OGLDs before insulin is started; therefore, the continuation or discontinuation of combination therapy warrants investigation \[[@b8]\]. Theoretically, individuals taking optimized doses of rosiglitazone and metformin combination may require less insulin to achieve target glycaemic control compared with insulin alone or insulin plus either oral agent. Additionally, weight gain might be controlled by the metformin component, but hypoglycaemia might increase or decrease. The purpose of the current study was therefore to compare the efficacy and safety of either continuing or discontinuing rosiglitazone + metformin fixed-dose combination (rosi + met) when starting insulin in people with Type 2 diabetes inadequately controlled on maximal dose rosi + met.

Research design and methods
===========================

Study population
----------------

Men and women aged 18--70 years with Type 2 diabetes (defined according to World Health Organization criteria \[[@b21]\]) were considered for this 24-week, multicentre, randomized, double-blind, parallel group study. Participants were recruited from 73 centres in five European countries. The study was conducted in accordance with Good Clinical Practice guidelines and the 1996 version of the Declaration of Helsinki. Written informed consent was obtained from all participants. The study protocol and informed consent were approved by an ethics committee or institutional review board according to local requirements.

Participants had body mass index ≥ 25.0 kg/m^2^, HbA~1c~ 7.1--10.0% at screening (visit 0; week −10), and were receiving ≥ 1500 mg metformin alone or in combination with other OGLDs at constant doses for ≥ 8 weeks prior to entry. Exclusion criteria included use of insulin in the 3 months before screening; a history of acidosis; ongoing oedema requiring pharmacological treatment; unstable or severe angina or any class of congestive heart failure; or myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting or stroke within 3 months. Other exclusion criteria included blood pressure \> 160/90 mmHg while on anti-hypertensive treatment, anaemia (Hb \< 11.0 g/dl in men and \< 10.0 g/dl in women), renal dysfunction (serum creatinine \> 135 µmol/l in men and \> 110 µmol/l in women), hepatic disease, and fasting serum C-peptide ≤ 0.50 nmol/l.

Study design
------------

Eligible participants were enrolled into an 8-week, single-blind, run-in phase. During this time, prior OGLD treatment was changed to rosi + met 8 + 2000 mg (4 + 1000 mg twice daily). At the end of the run-in period, eligible participants with a clinic fasting plasma glucose (FPG) ≥ 7.0 mmol/l 2 weeks previously (*n* = 324) were randomized to either rosi + met 8 + 2000 mg plus insulin (*n* = 163) or matched placebo plus insulin (*n* = 161) double-blind for 24 weeks. Randomization was remote and concealed from centres, was gender stratified, and used a block randomization method. The combination of a thiazolidinedione with insulin remains investigational at the time of writing and is not a licensed indication in some countries.

The safety population included all randomized individuals who received at least one dose of double-blind study medication (rosi + met *n* = 162; placebo *n* = 160), and the intent-to-treat (ITT) population included all those who had at least one valid on-therapy observation for an efficacy variable (rosi + met *n* = 161; placebo *n* = 158). The baseline clinical characteristics of the groups were well matched ([Table 1](#tbl1){ref-type="table"}).

###### 

Clinical characteristics at randomization of the people with Type 2 diabetes studied

                                                                        Rosiglitazone + metformin and insulin   Placebo and insulin
  --------------------------------------------------------------------- --------------------------------------- ---------------------
  Safety population (*n*)                                               162                                     160
  Age (years)                                                           57.2 ± 8.6                              56.9 ± 9.1
  Sex \[M/F, *n* (%)\]                                                  84/78 (52/48)                           85/75 (53/47)
  Race \[white/other, *n* (%)\]                                         158/4 (98/2)                            158/2 (99/1)
  Body weight (kg)                                                      88.9 ± 15.3                             92.1 ± 16.8
  Body mass index (kg/m^2^)                                             31.8 ± 4.7                              32.5 ± 5.2
  Duration from diagnosis (years)                                        9.2 ± 6.1                               8.5 ± 6.0
  Prior glucose-lowering drug use \[one/two daily at entry, *n* (%)\]   33/129 (20/80)                          31/129 (19/81)

Mean ± [sd]{.smallcaps}, or *n* (%).

Baseline blood glucose control data are given in [Table 2](#tbl2){ref-type="table"}.

###### 

Changes in efficacy and health perception measures from baseline to week 24 when starting insulin and continuing or discontinuing rosiglitazone + metformin fixed-dose combination therapy

                                                                     Rosiglitazone + metformin and insulin         Placebo and insulin   Treatment comparison as difference or odds ratio                                                                     
  ------------------------------------------------------------------ --------------------------------------------- --------------------- -------------------------------------------------- ------------------- --------------------------------------------- ----------
  Insulin dose (U/day)                                               21.7 ± 0.4[\*](#tf2-1){ref-type="table-fn"}   33.5 ± 1.5            23.1 ± 0.4[\*](#tf2-1){ref-type="table-fn"}        59.0 ± 3.0          −26.6 (−37.7, −15.5)                          \< 0.001
  HbA~1c~ (%)                                                         8.7 ± 0.1                                     6.8 ± 0.1             8.8 ± 0.1                                          7.5 ± 0.1          −0.7 (−0.8, −0.5)                             \< 0.001
  Clinic FPG (mmol/l)                                                10.9 ± 0.2                                     7.5 ± 0.2            10.8 ± 0.2                                          8.9 ± 0.2          −1.4 (−1.9, −0.9)                             \< 0.001
  Target achievers \[*n* (%)\]:                                                                                                                                                                                                                               
   HbA~1c~ ≤ 6.5%                                                                                                  74 (46)                                                                  29 (19)             4.1 (2.4, 6.9)                                \< 0.001
   HbA~1c~ \< 7.0%                                                                                                 113 (70)                                                                 53 (34)             5.0 (3.0, 8.1)                                \< 0.001
   Clinic FPG ≤ 6.5 mmol/l                                                                                         58 (36)                                                                  25 (16)             3.0 (1.8, 5.2)                                \< 0.001
  Mean daily SMBG[†](#tf2-2){ref-type="table-fn"} (mmol/l)           10.0 ± 0.2                                    6.8 ± 0.1              10.0 ± 0.2                                        8.2 ± 0.2                                                         
  Hypoglycaemia events (*n*)                                                                                       166                                                                      130                 1.1 (0.6, 2.1)                                NS
    ≥ 1 event \[*n* (%)\][†](#tf2-2){ref-type="table-fn"}                                                          40 (25)                                                                  43 (27)                                                           
    ≥ 6 events \[*n* (%)\][†](#tf2-2){ref-type="table-fn"}                                                         9 (5)                                                                    5 (3)                                                             
  Body weight (kg)                                                   89.6 ± 1.3                                    93.2 ± 1.3            91.2 ± 1.3                                         93.7 ± 1.3          1.1 (0.2, 2.1)                                0.021
  C-peptide (nmol/l)[‡](#tf2-3){ref-type="table-fn"}                 0.75 (0.58, 0.97)                             0.66 (0.41, 0.89)     0.77 (0.59, 1.01)                                  0.70 (0.45, 0.97)   −0.10 (−0.27, 0.07) vs. −0.10 (−0.25, 0.12)   NS
  Proinsulin (pmol/l)[‡](#tf2-3){ref-type="table-fn"}                6.4 (3.8, 9.7)                                4.8 (2.6, 10.3)       6.8 (4.3, 10.1)                                    6.6 (4.0, 14.2)     −0.8 (−4.3, 2.5) vs. 1.0 (−1.8, 4.6)          \< 0.001
  Proinsulin:C-peptide[‡](#tf2-3){ref-type="table-fn"} (pmol/nmol)   8.1 (5.0, 12.7)                               7.6 (4.5, 14.0)       9.1 (6.2, 13.2)                                    10.7 (7.6, 17.6)    −0.3 (−3.7, 3.2) vs. 2.0 (−0.8, 6.6)          \< 0.001
  DTSQs score                                                        28.5 ± 0.6                                    29.2 ± 0.5            27.7 ± 0.6                                         27.4 ± 0.6          1.5 (0.2, 2.7)                                0.024
  DTSQc score                                                        ---                                           11.5 ± 0.8            ---                                                9.6 ± 0.7           1.9 (0.4, 3.4)                                0.014

FPG, clinic/laboratory fasting plasma glucose; NS, non-significant; SMBG, self-monitored blood glucose.

Mean ± [se]{.smallcaps}, *n* (%), median (IQ range), or treatment difference from baseline to week 24 (95% CI).

ITT population with LOCF (insulin dose without LOCF), or safety population for hypoglycaemia.

Starting insulin dose taken as baseline.

Observational data without statistical comparison.

Hormonal data are analysed non-parametrically, and given as median (25--75%ile), with change from baseline rather than treatment difference.

All participants were started on 24 U/day of locally sourced premixed insulin (12 U before breakfast and 12 U before the evening meal), the 'baseline' dose. Following training provided by the investigator or a trained designee, participants were asked to make self-monitored blood glucose (SMBG) measurements using a blood glucose meter calibrated to whole blood, and to record the results on diary cards. On beginning insulin they were requested to test four times daily to drive insulin dose adjustment according to protocol-specific algorithms, every 3--5 days until a target pre-breakfast and pre-evening meal blood glucose level of ≤ 6.5 mmol/l was achieved. After the target was reached, tests were requested to be carried out twice daily three times weekly, but four times daily for 3--5 days prior to the next clinic visit. If an SMBG level ≤ 4.0 mmol/l was recorded that could not be explained, the insulin dose was to be decreased by 10%.

Participants were educated by a qualified nutrition professional on following a diet designed to maintain their current weight. Individuals were discontinued from the study (see numbers below) if they experienced unacceptable hypoglycaemia, exacerbation of ongoing oedema during the run-in, new oedema prior to randomization or lack of efficacy defined by increased FPG or symptomatic hyperglycaemia deemed by the investigator to be a safety risk.

Study assessments
-----------------

Eleven study visits were scheduled from screening (week −10) to study end, at which fasting blood samples were taken (before the morning insulin injection). Assays were performed at a central laboratory (Quest Diagnostics, Heston, UK) using standard assays. The primary efficacy end point was the change in HbA~1c~ from baseline (week 0) to week 24. HbA~1c~ was measured by high-performance liquid chromatography (HPLC) using a Diabetes Control and Complications Trial (DCCT)-harmonized assay. Secondary end points included change in office-sampled laboratory-measured FPG from baseline to week 24, the proportion of participants who achieved HbA~1c~ and FPG targets, daily insulin dose, and hypoglycaemic events during the last 12 weeks of the study (in the expectation that insulin dose would be relatively stable by week 12). Participants were instructed to record symptomatic hypoglycaemia on diary cards with an SMBG result. Investigators were asked to confirm hypoglycaemia by careful history and the SMBG result. Compliance with insulin-dose algorithms was assessed at week 24 based on diary card records. This suggested compliance 'all of the time' or 'most of the time' by 124 (77%) participants in the rosi + met group and by 110 (69%) participants in the placebo group.

Changes in islet B-cell dysfunction were assessed through changes in proinsulin, C-peptide and proinsulin:C-peptide ratio. Health outcome variables were measured using Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and DTSQ change (DTSQc) total scores. These are self-administered and validated instruments \[[@b22]\]. Safety variables included adverse events (AEs) recorded by the investigator and assessed as mild, moderate or severe.

Statistical analysis
--------------------

The differences between treatment groups for mean change in HbA~1c~, FPG and DTSQs were assessed by an [ancova]{.smallcaps} model with terms for treatment, country, gender and baseline measurement. DTSQc was analysed similarly but with no baseline measurement. Analysis of treatment difference for total daily insulin dose was assessed using a repeated-measures analysis model with terms for treatment, country, gender, time (visit) and treatment-by-time (visit). C-peptide, proinsulin and proinsulin:C-peptide ratio data were analysed non-parametrically as change from baseline because of non-normal data distribution. Comparisons between treatment groups in the proportion of participants achieving HbA~1c~ ≤ 6.5% and \< 7.0%, and FPG ≤ 6.5 mmol/l were assessed using a logistic regression model with terms for treatment, gender and baseline measurement, with treatment comparison estimated as odds ratios.

Treatment difference for the total number of hypoglycaemic events in the last 12 weeks of the study was assessed based on Poisson regression model analysis with terms of treatment, gender and baseline measurement, accounting for duration of therapy. Safety measures were summarized by treatment group.

Results
=======

Study population
----------------

Twenty-seven participants (8%) from the safety population withdrew during the double-blind phase. The primary reasons were participant decision \[6 (4%) in each group\] and AEs \[rosi + met 4 (2%); placebo 4 (3%)\]. Withdrawals of note included in the rosi + met group two as a result of oedema and one as a result of abdominal discomfort, and in the placebo group one as a result of weight gain. One person on rosi + met and two on placebo were withdrawn by investigators for lack of efficacy, and three on rosi + met and one on placebo for protocol violation.

Insulin doses
-------------

Daily insulin dose in the two groups was diverging by week 2 ([Fig. 1](#fig01){ref-type="fig"}) and was significantly lower in the rosi + met group at every visit from week 2, with treatment differences increasing with time. Most dose adjustment occurred in the first 4 weeks in both groups ([Fig. 1](#fig01){ref-type="fig"}). At week 24, there was a model-adjusted mean difference of −26.6 (95% CI −37.7, −15.5) U/day, *P* \< 0.001 ([Table 2](#tbl2){ref-type="table"}).

![Time courses for daily insulin dose, HbA~1c~ and clinic FPG for people with Type 2 diabetes starting insulin while continuing rosiglitazone + metformin (□) or transferring to placebo (•). Data are mean ± [se]{.smallcaps} for ITT populations with LOCF, except for dose which is without LOCF. For statistical significance see Results and [Table 2](#tbl2){ref-type="table"}.](dme0024-0618-f1){#fig01}

Glycaemic control
-----------------

The group continuing rosi + met achieved significantly greater improvement in HbA~1c~ between baseline and week 24 compared with the placebo group \[difference −0.7 (−0.8, −0.5)%, *P* \< 0.001; [Fig. 1](#fig01){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}\]. A significantly greater proportion of people receiving rosi + met achieved treatment targets of HbA~1c~ ≤ 6.5 and \< 7.0% compared with those in the placebo group (*P* \< 0.001; [Table 2](#tbl2){ref-type="table"}); 46% in the rosi + met group achieved the stricter target.

The fall in clinic FPG was early and rapid in the group continuing rosi + met ([Fig. 1](#fig01){ref-type="fig"}). At week 24, there was a greater reduction in clinic FPG in the rosi + met group compared with the placebo group, with a difference between the two groups of −1.4 (−1.9, −0.9) mmol/l, *P* \< 0.001 ([Table 2](#tbl2){ref-type="table"}). A significantly greater proportion of individuals who received rosi + met achieved the clinic FPG target ≤ 6.5 mmol/l (*P* = 0.001; [Table 2](#tbl2){ref-type="table"}).

SMBG data were collected to assist in insulin dose titration and were not compared statistically. In the rosi + met group, mean daily SMBG measurement fell from 10.0 ± 0.2 mmol/l at baseline to 6.8 ± 0.1 mmol/l at week 24. The mean SMBG reduced from 10.0 ± 0.2 mmol/l to 8.2 ± 0.2 mmol/l in the placebo group ([Table 2](#tbl2){ref-type="table"}).

Hypoglycaemia and body weight
-----------------------------

During the last 12 weeks of the study, the number of participants who reported biochemically confirmed hypoglycaemia with and without symptoms was similar between groups: rosi + met vs. placebo 33 vs. 32 and 9 vs. 13, respectively. The number of participants who reported symptomatic hypoglycaemia which was not biochemically confirmed was also similar with rosi + met and placebo (5 vs. 5 individuals). The number of participants reporting at least one hypoglycaemic event of any kind during the last 12 weeks of the study was very similar in the two groups: 40 (25%) in the rosi + met group and 43 (27%) in the placebo group. Although the total number of reported events was higher with rosi + met (166 vs. 130 events), the event rate was not statistically significantly different ([Table 2](#tbl2){ref-type="table"}). No severe events or events leading to withdrawal from study medication occurred.

Body weight increased in both groups, with a significantly greater increase in the rosi + met group \[mean difference 1.1 (0.2, 2.1) kg (*P* = 0.021) [Table 2](#tbl2){ref-type="table"}\].

Islet B-cell function and dysfunction
-------------------------------------

Despite lower FPG levels with rosi + met (above), serum C-peptide levels were similar in the two groups at 24 weeks, with identical change from baseline ([Table 2](#tbl2){ref-type="table"}). Proinsulin levels, while similar at baseline, fell only in the rosi + met group, and were notably lower at 24 weeks, with a significantly different change in levels from baseline compared with the placebo group (*P* \< 0.001, [Table 2](#tbl2){ref-type="table"}). Consistent with these data, the proinsulin:C-peptide ratio change from baseline was also different in the two groups (*P* \< 0.001; [Table 2](#tbl2){ref-type="table"}).

Health perception measures
--------------------------

Measures of health perception suggested a greater level of treatment satisfaction in participants who received rosi + met compared with placebo. From baseline to week 24, the DTSQs score increased in the rosi + met group and decreased with placebo \[difference 1.5 (0.2, 2.7) points, *P* = 0.024; [Table 2](#tbl2){ref-type="table"}\]. The DTSQc total score, a measure of improvement in satisfaction, was significantly higher in the rosi + met group than in the placebo group at week 24 \[difference 1.9 (0.4, 3.4) points, *P* = 0.014; [Table 2](#tbl2){ref-type="table"}\].

Safety and tolerability
-----------------------

Both treatment regimens were generally well tolerated. A similar proportion of participants had on-therapy AEs in the two treatment groups: 60 people (38%) in the rosi + met group and 69 people (43%) with placebo. Six people (4%) in the rosi + met group and eight people (5%) in the placebo group had on-therapy non-fatal serious AEs. All were reported by the investigator as apparently unrelated to study medication. One death occurred before treatment with study drugs, and one on rosi + met as a result of circulatory arrest.

Twelve participants (7%) in the rosi + met group had oedema, compared with four (3%) in the placebo group; all were judged mild or moderate, but two cases in the rosi + met group led to withdrawal from the study. In those participants who developed oedema, mean weight gain was 4.0 ± 1.7 kg in the placebo group and 5.0 ± 0.8 kg in the rosi + met group. There were no cases of heart failure in either treatment group, but one occurrence of angina pectoris (judged severe) on rosi + met, associated with weight loss (−7.1 kg).

Conclusions
===========

In this randomized controlled study, the addition of insulin to rosi + met significantly improved glycaemic control and increased the proportion of individuals achieving glycaemic targets when compared with insulin alone. Importantly, these changes were seen despite markedly lower insulin doses in the group continuing on rosi + met, and with no difference in the proportion of participants reporting hypoglycaemia during the last 12 weeks of the study (the period for which the insulin dose was stable). This improved blood glucose control with lower insulin doses was reflected in improved treatment satisfaction measures, known to primarily reflect changes in perceived control \[[@b23]\]. A comparison between the insulin-sparing effect of rosi + met in this study and previous studies of OGLDs in combination with insulin suggests rosi + met may have an additional insulin-sparing effect over that seen with metformin plus insulin \[[@b2],[@b3]\].

The increased incidence of oedema in participants continuing on rosi + met compared with insulin plus placebo (7 vs. 3%) was lower than in a previous study of insulin plus rosiglitazone \[[@b19]\], although still measurable, and with no cases of heart failure. The lower rate of oedema in this study may reflect the gradual up titration of insulin therapy. The lower dose of insulin required with rosi + met may also have helped, as oedema associated with thiazolidinedione treatment is greater when thiazolidinediones are used in combination with insulin \[[@b20]\].

The significantly greater mean weight gain seen with rosi + met therapy in this study is consistent with a systematic review reporting that weight gain with thiazolidinediones in combination with insulin is consistently associated with improved glycaemic control \[[@b2]\]. The weight difference from the placebo group is consistent with the difference in blood glucose control \[[@b4]\]. The gain of 3.7 kg in the present study was less than the 5.3 kg previously observed when rosiglitazone 8 mg/day was used with insulin \[[@b19]\], suggesting that metformin may have a mitigating effect on the weight change, in line with previous reports of metformin added to insulin \[[@b2],[@b3]\] and of metformin plus rosiglitazone \[[@b10],[@b18]\].

Mechanistically, the lower insulin dose required in the rosi + met group supports the rationale for improving insulin sensitivity, as indicated by the combination of lower insulin requirements and lower HbA~1c~. Reducing the insulin dose may offer health benefits in terms of reducing the risk of hypoglycaemia \[[@b24]\] and hyperinsulinaemia \[[@b25]\], along with other putative benefits such as reducing the hunger stimulus and the frequency of injections, together with some cost offset. The lack of change in fasting serum C-peptide despite lower glucose levels implies improved islet B-cell function, but the present study cannot discriminate whether this is a direct effect or is secondary to the improvement in blood glucose and metabolic control. However, the fall in proinsulin and proinsulin:C-peptide ratio, not seen with the smaller improvement of glucose control in the placebo group, implies improved processing of proinsulin to insulin with continuation of rosi + met when starting insulin. More stable blood glucose control has been known for decades to be related to preservation of endogenous insulin secretion, and this may be another reason why the insulin sensitizers did not result in increased hypoglycaemia in this study. It is yet to be determined whether these changes have long-term implications for preservation of endogenous insulin secretion.

This study provides further support for current guidelines that recommend continuation of OGLD therapy while insulin is introduced \[[@b7],[@b8]\]. This study is also in agreement with recent studies suggesting that titration of insulin to achieve glycaemic targets allows improved glycaemic control while minimizing the risk of hypoglycaemia \[[@b26]--[@b28]\]. In the current study, almost half of the group randomized to rosi + met was able to achieve HbA~1c~ ≤ 6.5%, the target in the latest evidence-based guidelines such as those of the International Diabetes Federation \[[@b8],[@b29],[@b30]\], despite starting levels (mean 8.7%) well above usual recommendations for starting insulin. In contrast, less than one-third of those randomized to insulin plus placebo achieved this target.

There are several limitations that must be considered when making comparisons with other studies. The regimen used for insulin dose adjustment was less aggressive than in some recent studies \[[@b4],[@b19]\], which may account for the higher HbA~1c~ values obtained with insulin monotherapy here compared with studies that have used alternative insulin regimens \[[@b4]\]. In addition, it is important to note that, while the aim of this study was to examine continuation or discontinuation of rosi + met when initiating insulin, current guidelines advise the continuation of metformin when transferring patients to insulin \[[@b7],[@b8]\].

The present results appear to be generally applicable as a result of the inclusion of a typical Type 2 diabetes starter population in line with treatment recommendations, although excluding those with a history of cardiac failure \[[@b7],[@b8]\]. A future investigation could consider a comparator group treated with insulin added to metformin monotherapy; meanwhile, however, the results appear better than those achieved in other recent studies of insulin initiation in which OGLDs were continued \[[@b26],[@b28],[@b31]\], although inter-study comparisons must be made with caution.

In conclusion, the addition of insulin to rosi + met as a fixed-dose combination proved effective, well tolerated, and enabled more individuals to reach glycaemic targets, with a lower insulin dose requirement than for insulin monotherapy.
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AE

:   adverse event

DTSQ

:   Diabetes Treatment Satisfaction Questionnaire

FPG

:   fasting plasma glucose

HbA~1c~

:   glycated haemoglobin

ITT

:   intent-to-treat

OGLD

:   oral glucose-lowering drug

rosi + met

:   rosiglitazone + metformin fixed-dose combination

SMBG

:   self-monitored blood glucose

[^1]: This study was presented in abstract form at the Diabetes UK Professional Conference in Birmingham, UK, 29--31 March 2006.
